Findings

What do systematic reviews say?

607 questions · 641 findings · 77 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 114 · 17.8%GRADE not reported 25 · 3.9%Very low 170 · 26.5%Low 175 · 27.3%Moderate 123 · 19.2%High 34 · 5.3%

Corticosteroids vs placebo

Serious adverse events · adults with advanced cancer and cancer‐related fatigue

1 finding from 1 review

Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 118 participants
Very low

Corticosteroids vs placebo

QoL · adults with advanced cancer and cancer‐related fatigue

1 finding from 1 review

Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 118 participants
Very low

Corticosteroids vs modafinil

Fatigue relief ( · adults with advanced cancer and cancer‐related fatigue

1 finding from 1 review

Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Very low

Corticosteroids vs modafinil

Adverse events · adults with advanced cancer and cancer‐related fatigue

1 finding from 1 review

Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Very low

Corticosteroids vs modafinil

Serious adverse events · adults with advanced cancer and cancer‐related fatigue

1 finding from 1 review

Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Very low

Corticosteroids vs modafinil

Quality of life ( · adults with advanced cancer and cancer‐related fatigue

1 finding from 1 review

Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Very low

Corticosteroids vs no corticosteroid use

Incidence of coronary artery abnormalities · children diagnosed with Kawasaki disease

Corticosteroids probably leads to lower incidence of coronary artery abnormalities compared with no corticosteroid use (moderate certainty).

1 finding from 1 review

Corticosteroids for the treatment of Kawasaki disease in children 2022 · Cochrane Headline outcomes only
OR 0.32 [0.14, 0.75]
8 studies · 986 participants
Moderate

Corticosteroids vs no corticosteroid use

Mortality (all‐cause) · children diagnosed with Kawasaki disease

1 finding from 1 review

Corticosteroids for the treatment of Kawasaki disease in children 2022 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1075 participants
Moderate

Corticosteroids vs no corticosteroid use

Duration of clinical symptoms: fever and rash (days) · children diagnosed with Kawasaki disease

1 finding from 1 review

Corticosteroids for the treatment of Kawasaki disease in children 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 290 participants
Low

Corticosteroids vs no corticosteroid use

Time for laboratory parameters to normalise: CRP, ESR (days) Duration: N/A · children diagnosed with Kawasaki disease

1 finding from 1 review

Corticosteroids for the treatment of Kawasaki disease in children 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 178 participants
Moderate

Corticosteroids vs no corticosteroid use

Length of hospital stay · children diagnosed with Kawasaki disease

1 finding from 1 review

Corticosteroids for the treatment of Kawasaki disease in children 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 119 participants
Moderate

Corticosteroids vs no corticosteroid use

Longer term (> 1 year after disease onset) coronary morbidity (non‐aneurysmal) · children diagnosed with Kawasaki disease

The review found no eligible studies for this question.

1 finding from 1 review

Corticosteroids for the treatment of Kawasaki disease in children 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs placebo

Pain resolution · patients with sore throat

Corticosteroids leads to higher complete resolution of pain at 24 hours compared with placebo (high certainty).

2 findings from 1 review

Corticosteroids as standalone or add‐on treatment for sore throat 2020 · Cochrane Headline outcomes only
RR 2.4 [1.29, 4.47]
5 studies · 851 participants
High
Corticosteroids as standalone or add‐on treatment for sore throat 2020 · Cochrane Headline outcomes only
RR 1.5 [1.27, 1.76]
4 studies · 774 participants
High

Corticosteroids vs placebo

Time to initial pain relief (minutes) · patients with sore throat

1 finding from 1 review

Corticosteroids as standalone or add‐on treatment for sore throat 2020 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 840 participants
Moderate

Corticosteroids vs placebo

Mean time to resolution of pain · patients with sore throat

1 finding from 1 review

Corticosteroids as standalone or add‐on treatment for sore throat 2020 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 695 participants
Moderate

Corticosteroids vs placebo

Absolute reduction in pain measured by VAS · patients with sore throat

1 finding from 1 review

Corticosteroids as standalone or add‐on treatment for sore throat 2020 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1004 participants
Moderate

Corticosteroids vs placebo

Adverse events · patients with sore throat

Corticosteroids showed no clear difference in adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Corticosteroids as standalone or add‐on treatment for sore throat 2020 · Cochrane Headline outcomes only
RR 1.08 [0.31, 3.77]
2 studies · 690 participants
Moderate

Corticosteroids vs placebo

Recurrence · patients with sore throat

Corticosteroids showed no clear difference in recurrence/relapse rates compared with placebo (moderate certainty).

1 finding from 1 review

Corticosteroids as standalone or add‐on treatment for sore throat 2020 · Cochrane Headline outcomes only
RR 0.52 [0.16, 1.73]
3 studies · 353 participants
Moderate

Corticosteroids vs placebo

Days missed from work or school · patients with sore throat

1 finding from 1 review

Corticosteroids as standalone or add‐on treatment for sore throat 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 405 participants
Moderate

Corticosteroids vs placebo or usual care

28‐Day all‐cause mortalitya · children and adults with sepsis

Corticosteroids probably leads to lower 28‐Day all‐cause mortalitya compared with placebo or usual care (moderate certainty).

1 finding from 1 review

Corticosteroids for treating sepsis in children and adults 2019 · Cochrane Headline outcomes only
RR 0.91 [0.84, 0.99]
50 studies · 11233 participants
Moderate